Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Actuate Therapeutics IncNASDAQ: ACTU

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$5.62M, compared with -$6.31M a year earlier. Trailing-twelve-month EBITDA was -$21.52M.

Context

  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +11.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.62M-23.6% QoQ
Last fiscal yearDec 2025
-$22.21M+11.7% YoY
LTMMar 2026
-$21.52M+14.5% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.0%+100.0%+89.0 pp
1 year+11.7%+100.0%+88.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(22.21M) USD
Year-over-year change
+11.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +14.5% is the 6th highest of 9, against a peer median of +22.9%.
ACTU Competitors
EBITDA for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$449.13M USD+489.9%——
SPROSpero Therapeutics, Inc.LTM Mar 2026$14.89M USD+121.1%—27.2%
ACTUActuate Therapeutics IncLTM Mar 2026-$21.52M USD+14.5%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026-$37.68M USD+23.9%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$41.87M USD+24.2%—3650.0%
MOLNMolecular Partners AGLTM Mar 2026-CHF 63.08M CHF-8.3%——
PEPGPepGen Inc.LTM Mar 2026-$75.99M USD+22.0%——
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
ALECAlector, Inc.LTM Mar 2026-$116.42M USD-1.3%—632.1%
Peer median (excluding ACTU) —+22.9%—632.1%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development16.39M21.71M18.68M10.29M
Selling, General & Admin3.82M3.27M6.48M12.2M
Operating Expenses20.21M24.97M25.16M22.5M
Depreciation & Amortization63.61K272.85K2.14M0
EBITDA(20.08M)(24.43M)(25.16M)(22.21M)
EBITDA Margin————
Operating Income(20.21M)(24.97M)(25.16M)(22.5M)
Operating Margin————
Interest Income27.03K352.67K222.29K287.71K
Interest Expense16.2K43.64K(18.72K)20.25K
Other Income / Expenses47.41K229.21K(2.12M)267.46K
Income Before Tax(20.16M)(24.74M)(27.28M)(22.23M)
Pre-Tax Margin————
Income Tax Expense008000
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Net Margin————
EPS (Basic)(1.34)(1.65)(3.26)(1.06)
EPS (Diluted)(1.34)(1.65)(3.26)(1.06)
Weighted Avg Shares15.03M15.03M19.51M21.02M
Weighted Avg Shares (Diluted)15.03M15.03M19.51M21.02M

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.